AC
ACAD
Market ClosedACADIA Pharmaceuticals Inc.
US
798 employees
CEO: Catherine E. Owen Adams
Founded: 2004
$24.84
+$0.00(+NaN%)
Market Cap
4.25B
Beta
0.80
52W Range
N/A
Dividend Yield
0.00%
Forecasting Analysis
AI-powered predictions and statistical risk modeling for short-term price movements
AI Insight:
ACADIA's AI short-term forecast is projecting modest downside risk, indicating near-term caution. Analyst consensus shows a strong, broadly aligned bullish outlook with moderate variability in price targets. This contrast suggests potential short-term volatility amid prevailing longer-term confidence.
Current Price
N/A
Last closing price
Price Prediction
Machine learning prediction based on historical price patterns
Period:
Analyst Price Target for ACAD
Loading analyst price targets...
Wall Street Forecasts
Revenue Forecast
Past Growth
N/A
Based on Historical CAGR
Forward Growth
N/A
Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
Revenue Analysis
Comparison of Actual and Estimated Revenues
Loading chart data...
Revenue growth steady at 0.0%.
Operating Profitability Forecast
Past Growth
N/A
EBITDA Historical CAGR
Forward Growth
N/A
EBITDA Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EBITDA Analysis
Comparison of Actual and Estimated EBITDA
Loading chart data...
EBITDA maintaining 0.0% trajectory.
Earnings Per Share Forecast
Past Growth
N/A
EPS Historical CAGR
Forward Growth
N/A
EPS Projected CAGR
Analyst Accuracy
0%
Estimate Accuracy
EPS Analysis
Comparison of Actual and Estimated Earnings Per Share
Loading chart data...
EPS growth stable around 0.0%.
Explore ACAD
ACAD in the Healthcare
Mid Cap